GO:0001664 G protein-coupled receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001664 (G protein-coupled receptor binding) is a molecular function defined as binding to a G protein-coupled receptor (GPCR).
• GPCRs are the largest family of membrane receptors and are activated by diverse ligands, leading to conformational changes that engage heterotrimeric G proteins.
• The binding event is central to GPCR pharmacology, including orthosteric, allosteric, and biased agonism.
• Key genes include ADRB2, DRD2, AGTR1, and many others that encode GPCRs or their interacting partners.
• Dysregulation of GPCR binding underlies numerous diseases, including neuropathic pain, inflammation, and cancer.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of GPCR binding and signaling.
Description
G protein-coupled receptor binding (GO:0001664) is a molecular function that describes the interaction of a protein or ligand with a G protein-coupled receptor (GPCR). GPCRs constitute the largest family of cell surface receptors and mediate responses to hormones, neurotransmitters, and environmental stimuli. This binding event is the first step in a cascade that ultimately leads to heterotrimeric G protein activation and downstream signaling. Understanding the molecular details of GPCR binding is fundamental to pharmacology and drug discovery, as many therapeutic agents target these receptors. Recent advances in structural biology have revealed how ligand binding induces conformational changes in GPCRs that enable coupling to G proteins. Moreover, the concept of biased agonism, where different ligands stabilize distinct receptor conformations, has expanded the pharmacological landscape. Researchers studying GPCR binding often employ techniques such as GTPγS release assays to quantify receptor activation. The binding function is not limited to classical GPCRs; adhesion GPCRs also engage in complex binding interactions with extracellular matrix components. Given the broad physiological and pathological roles of GPCRs, GO:0001664 is a critical annotation for understanding signal transduction.
G protein-coupled receptor binding At A Glance
| GO ID | GO:0001664 |
|---|---|
| GO term | G protein-coupled receptor binding |
| Ontology | molecular_function |
| Synonym | G protein coupled receptor binding; G-protein coupled receptor binding; G protein coupled receptor ligand; G-protein-coupled receptor ligand |
| Major function | Binding to a G protein-coupled receptor, initiating or modulating signal transduction. |
| Related receptors | GPCRs such as adrenergic, dopaminergic, angiotensin, and melatonin receptors. |
| Signaling outcome | Activation of heterotrimeric G proteins and downstream effectors. |
| Pharmacological relevance | Target of many therapeutic agonists, antagonists, and allosteric modulators. |
What Is GO:0001664?
According to the Gene Ontology, GO:0001664 (G protein-coupled receptor binding) is defined as the binding to a G protein-coupled receptor. This molecular function encompasses the physical interaction between a ligand or protein and a GPCR, which typically leads to receptor activation or modulation of its activity. The term is used to annotate gene products that directly bind to GPCRs, including endogenous ligands, synthetic agonists, antagonists, and intracellular proteins that interact with the receptor.
Why Is G protein-coupled receptor binding Important in Cell Biology?
G protein-coupled receptor binding is a fundamental molecular event that governs cellular responses to a vast array of external signals. Because GPCRs are involved in nearly every physiological process, from neurotransmission to immune regulation, understanding their binding mechanisms is essential for both basic biology and drug development. The binding event determines the specificity and efficacy of signal transduction, and its dysregulation is implicated in numerous diseases, including cancer, cardiovascular disorders, and neurological conditions. Furthermore, the ability to design ligands that selectively modulate GPCR binding has led to breakthroughs in precision medicine.
• GPCRs are the largest family of membrane receptors and are targeted by approximately one-third of all approved drugs.
• Binding to GPCRs initiates signaling cascades that control heart rate, mood, metabolism, and immune responses.
• Biased agonism at GPCRs allows selective activation of beneficial pathways while avoiding side effects.
• Adhesion GPCRs mediate cell-cell and cell-matrix interactions, with roles in development and tissue homeostasis.
• GPCR binding is critical for pain perception and inflammation, as shown for GPR39.
• Melatonin receptor binding regulates circadian rhythms and sleep.
• Quantitative methods such as GTPγS release assays are used to measure GPCR activation.
• CRISPR screens can identify genes that modulate GPCR binding and signaling.
• Dysregulated GPCR binding is associated with neuropathic pain and chronic inflammation.
• Understanding GPCR binding at the structural level informs rational drug design.
What Happens During G protein-coupled receptor binding?
Ligand recognition and initial binding
In simple terms: A ligand docks into the receptor's binding pocket.
The binding event begins when a ligand, such as a hormone or neurotransmitter, interacts with the orthosteric site of a GPCR. This interaction is driven by non-covalent forces including hydrogen bonds, hydrophobic interactions, and ionic bonds. Structural studies have revealed that ligand binding stabilizes distinct receptor conformations, which is the basis for pharmacological specificity. For example, melatonin binds to its receptors (MT1 and MT2) through a conserved pocket, triggering conformational changes.
Conformational change and G protein coupling
In simple terms: The receptor changes shape to grab a G protein.
Upon ligand binding, GPCRs undergo conformational rearrangements, particularly in transmembrane helix 6, that expose a cavity for heterotrimeric G protein coupling. This activation process is highly dynamic and can be influenced by the ligand's efficacy. The activated receptor acts as a guanine nucleotide exchange factor (GEF) for the Gα subunit, promoting GDP release and GTP binding.
G protein activation and downstream signaling
In simple terms: The G protein turns on and sends a signal inside the cell.
Once GTP is bound, the Gα subunit dissociates from Gβγ and both can modulate effector proteins such as adenylyl cyclase or ion channels. The GTPγS release assay is a common method to measure this activation step. The duration and intensity of signaling are tightly regulated by factors like GTPase activity and arrestin recruitment.
Biased agonism and functional selectivity
In simple terms: Different ligands can make the receptor signal in different ways.
Not all ligands that bind a GPCR activate the same downstream pathways. Biased agonists stabilize specific receptor conformations that preferentially engage certain G proteins or β-arrestin, leading to distinct physiological outcomes. This concept has therapeutic implications, as biased ligands can potentially separate beneficial effects from side effects.
Key Genes Involved in GO:0001664 G protein-coupled receptor binding
The following genes encode GPCRs or proteins that directly bind to GPCRs, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor; binds catecholamines | Model for GPCR activation and biased agonism |
| DRD2 | Dopamine D2 receptor; binds dopamine | Target for antipsychotics and Parkinson's disease research |
| AGTR1 | Angiotensin II receptor type 1; binds angiotensin II | Cardiovascular and hypertension studies |
| MTNR1A | Melatonin receptor 1A; binds melatonin | Circadian rhythm and sleep research |
| MTNR1B | Melatonin receptor 1B; binds melatonin | Metabolic and circadian studies |
| GPR39 | G protein-coupled receptor 39; binds zinc and other ligands | Neuropathic pain and inflammation |
| ADGRL1 | Adhesion G protein-coupled receptor L1 | Cell adhesion and signaling |
| ADGRG1 | Adhesion G protein-coupled receptor G1 | Brain development and cancer |
| CXCR4 | C-X-C chemokine receptor type 4; binds CXCL12 | Cancer metastasis and HIV entry |
| CCR5 | C-C chemokine receptor type 5; binds chemokines | HIV infection and inflammation |
| OPRM1 | Mu-opioid receptor; binds opioids | Pain management and addiction |
| HTR1A | Serotonin 1A receptor; binds serotonin | Depression and anxiety research |
| AVPR2 | Vasopressin V2 receptor; binds vasopressin | Kidney function and diabetes insipidus |
| GCGR | Glucagon receptor; binds glucagon | Glucose metabolism and diabetes |
| GLP1R | Glucagon-like peptide-1 receptor; binds GLP-1 | Diabetes and obesity therapeutics |
| FZD4 | Frizzled-4; binds Wnt ligands | Developmental signaling and cancer |
| SMO | Smoothened; binds Hedgehog ligands | Cancer and developmental biology |
How Is G protein-coupled receptor binding Regulated?
The binding of ligands to GPCRs is regulated at multiple levels. Receptor expression levels, post-translational modifications, and the presence of allosteric modulators can influence binding affinity and efficacy. Additionally, phosphorylation of the receptor by GRKs and subsequent arrestin recruitment can desensitize the receptor, reducing its ability to bind and activate G proteins. Biased agonism further adds a layer of regulation by altering which signaling pathways are engaged upon binding. The GTPγS release assay can be used to quantify the functional consequences of these regulatory mechanisms.
G protein-coupled receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GPR39 | Neuropathic pain, chronic inflammation | Knockout mouse, overexpression in sensory neurons |
| MTNR1A/MTNR1B | Circadian rhythm disorders, insomnia | Point mutation knock-in in mice |
| CXCR4 | Cancer metastasis, HIV | Knockout in cancer cell lines, knock-in of humanized receptor |
| ADRB2 | Asthma, cardiovascular disease | Biased agonist testing in knockout models |
| GLP1R | Type 2 diabetes, obesity | Overexpression and point mutation in pancreatic beta cells |
GPCR binding in neuropathic pain and inflammation
GPR39, a GPCR, has been shown to alleviate neuropathic pain and chronic inflammation when activated. Binding of ligands to GPR39 modulates pain signaling pathways, suggesting that targeting this receptor could be therapeutic. Dysregulation of GPCR binding in sensory neurons contributes to hyperalgesia and allodynia.
GPCR binding in cancer
Many GPCRs, such as CXCR4 and CCR5, are overexpressed in various cancers and promote metastasis and angiogenesis upon binding to their chemokine ligands. Biased agonists that selectively activate tumor-suppressive pathways are being explored as anticancer agents.
GPCR binding in metabolic and circadian disorders
Melatonin receptors (MT1 and MT2) bind melatonin to regulate circadian rhythms; dysregulation of this binding is linked to sleep disorders and metabolic syndrome. Similarly, GLP-1 receptor binding is a key target for diabetes therapy.
From G protein-coupled receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GPCR binding affect downstream signaling? | Knockout cell line or animal model |
| How does a specific point mutation alter ligand binding affinity? | Point mutation knock-in via CRISPR |
| Can a tagged GPCR be used to track trafficking? | Knock-in of fluorescent or epitope tag |
| What is the effect of GPCR overexpression on cell proliferation? | Overexpression stable cell line |
| Which genes modulate GPCR binding in a genome-wide screen? | CRISPR library screening |
| How does biased agonism affect physiological outcomes? | Knock-in mouse with humanized receptor |
How to Study the G protein-coupled receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTPγS release assay | G protein activation | Quantifying agonist efficacy |
| Receptor trafficking assay | Internalization and recycling | Studying desensitization |
| Cryo-EM | Receptor structure and conformational changes | Understanding activation mechanisms |
| CRISPR knockout screen | Gene essentiality for GPCR binding | Identifying novel regulators |
| Point mutation knock-in | Effect of specific mutations on binding | Structure-function studies |
| Overexpression | Gain-of-function effects | Screening for oncogenic potential |
| Biased agonism profiling | Pathway-specific activation | Drug discovery |
GTPγS release assay
The GTPγS release assay measures the activation of G proteins following GPCR binding. It quantifies the exchange of GDP for GTPγS, a non-hydrolyzable analog, providing a direct readout of receptor-mediated G protein activation.
Quantitation of receptor trafficking
Plasma membrane receptor trafficking can be quantified using imaging and biochemical methods to assess how binding affects receptor internalization and recycling.
Structural biology approaches
X-ray crystallography and cryo-electron microscopy have elucidated the molecular basis of GPCR activation and ligand binding, revealing conformational changes and interaction interfaces.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate GPCR binding and signaling, offering unbiased discovery of novel modulators.
How CRISPR Can Be Used to Study GO:0001664 G protein-coupled receptor binding
Knockout
CRISPR knockout of a GPCR gene eliminates receptor expression, allowing researchers to assess the contribution of that receptor to ligand binding and downstream signaling. This is particularly useful for validating drug targets and understanding receptor-specific effects.
Point Mutation
Introducing specific point mutations into a GPCR gene via CRISPR can mimic naturally occurring variants or disrupt key binding residues. This helps dissect the molecular determinants of ligand binding and activation.
Knock-in
Knock-in of a tagged or humanized GPCR allows for tracking receptor localization, trafficking, and interaction with ligands in a physiological context. It also enables the study of species-specific pharmacology.
Overexpression
Overexpression of a GPCR using CRISPR activation or cDNA delivery can amplify signaling and reveal gain-of-function phenotypes, such as enhanced proliferation or altered metabolism.
How EDITGENE Supports G protein-coupled receptor binding Research
Researchers studying G protein-coupled receptor binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. This requires precise genetic models that can isolate the contribution of individual receptors or binding partners.
Contact EDITGENE today to design your custom CRISPR model for G protein-coupled receptor binding research.
Frequently Asked Questions About G protein-coupled receptor binding
What is GO:0001664?
GO:0001664 is the Gene Ontology term for G protein-coupled receptor binding, defined as binding to a G protein-coupled receptor.
What genes are involved in G protein-coupled receptor binding?
Genes encoding GPCRs such as ADRB2, DRD2, AGTR1, and MTNR1A, as well as their ligands and interacting proteins.
How does G protein-coupled receptor binding lead to signaling?
Ligand binding induces conformational changes that allow the receptor to activate heterotrimeric G proteins, triggering downstream cascades.
What diseases are associated with GPCR binding?
Neuropathic pain, inflammation, cancer, metabolic disorders, and circadian rhythm disorders.
What methods are used to study GPCR binding?
GTPγS release assays, receptor trafficking assays, cryo-EM, and CRISPR screens.
Can CRISPR be used to study GPCR binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect GPCR function.
What is biased agonism in GPCR binding?
Biased agonism refers to ligands that stabilize distinct receptor conformations, leading to preferential activation of specific signaling pathways.
How is GPCR binding regulated?
Regulation occurs through receptor expression, post-translational modifications, allosteric modulators, and desensitization mechanisms.
What is the role of adhesion GPCRs in binding?
Adhesion GPCRs mediate cell-cell and cell-matrix interactions and have diverse roles in development and disease.
Why is GPCR binding important for drug discovery?
Many drugs target GPCRs, and understanding binding mechanisms enables rational design of agonists, antagonists, and biased ligands.
Conclusion
G protein-coupled receptor binding (GO:0001664) is a cornerstone molecular function that underpins cellular communication and is implicated in a wide range of physiological and pathological processes. Advances in structural biology, pharmacology, and CRISPR-based genetic models continue to unravel the complexities of GPCR binding, offering new opportunities for therapeutic intervention. Researchers equipped with precise tools to manipulate GPCR genes can accelerate the translation of basic findings into clinical applications.
References
- 1. Weis WI et al.. 2018. The Molecular Basis of G Protein-Coupled Receptor Activation.. Annu Rev Biochem 87:897-919 PMID: 29925258
- 2. Bräuner-Osborne H et al.. 2020. G protein-coupled receptor pharmacology-The next generation.. Basic Clin Pharmacol Toxicol 126 Suppl 6:3-4 PMID: 31301209
- 3. Okamoto HH et al.. 2024. Melatonin receptor structure and signaling.. J Pineal Res 76(3):e12952 PMID: 38587234
- 4. Gurevich VV. 2025. Rational design of biased G protein-coupled receptor agonists.. Mol Pharmacol 107(12):100089 PMID: 41349424
- 5. Rosenkilde MM et al.. 2023. Adhesion G protein-coupled receptor's structure, function and role in biology-Status from the 10(th) adhesion GPCR workshop in Copenhagen, 2022.. Basic Clin Pharmacol Toxicol 133(4):281-285 PMID: 37635311
- 6. Cheng F et al.. 2024. Activation of G protein-coupled receptor 39 alleviates neuropathic pain and chronic inflammation.. J Biochem Mol Toxicol 38(1):e23545 PMID: 37842769
- 7. Wager-Miller J et al.. 2023. Quantitation of Plasma Membrane (G Protein-Coupled) Receptor Trafficking in Cultured Cells.. Methods Mol Biol 2576:395-406 PMID: 36152205
- 8. Bohn LM et al.. 2025. Characterization of the GTPγS release function of a G protein-coupled receptor.. Nat Commun 16(1):11193 PMID: 41407695
